Test of the Tool for Preventing and Managing Drug Interaction Involving HMG-CoA Reductase Inhibitor within Pharmacies
Article Sidebar
Main Article Content
Abstract
Objective: To test the use of tool for pharmacists in preventing and managing drug interactions (DIs) involving the HMG-CoA reductase inhibitor. Method: The developed tool was composed of images of the HMG-CoA reductase inhibitors, DI reminder plates on the drug shelves and flow charts of DI management of 10 common drugs in pharmacies with evidences on DIs at the levels 1-3 with the HMG-CoA reductase inhibitors. The tool was tested for 4 weeks (during March, 2018) at ten accredited community pharmacies in Bangkok area. The researchers collected the data on frequency of the use of the tool, drugs involved in DI, DI management according to the flow chart of the tool. The study also assessed satisfaction among pharmacists regarding the tool. Results: The pharmacists identified 145 prescribing or drug asking by patients with potential DIs involving the HMG-CoA reductase inhibitors. Use of the tool helped identify 18 potential DIs involving the HMG-CoA reductase inhibitors (12.41%). Seventeen of these DIs were managed according to the flow chart within the tool. Three most common drugs with DIs involving the HMG-CoA reductase inhibitors that were prescribed or commonly asked by patients included clarithromycin, fluconazole and gemfibrozil for 41, 28, 17 times
( 28.27%, 19.31%, 11.72%, respectively) . The most common drug pairs with DI were amlodipine/simvastatin (4 times), clarithromycin/simvastatin (3 times), clarithromycin/atorvastatin (2 times) and colchicine/atorvastatin (2 times). Pharmacists were satisfied with images of drugs, reminder plates on the drug shelves and the flow charts for DI management with the scores of 3.8±0.4, 3.8±0.4, and 3.6±0.6 out of the full score of 5, respectively. The subjects suggested that the tool should be expanded to commonly dispensed drugs in pharmacy to cover more medications
available in the stores. Conclusion: The developed tool for preventing and managing DI between the HMG-CoA reductase inhibitors and medications available in drugstores was practical in helping pharmacists to identify and manage DI leading to the safe use of drugs in the pharmacies.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Thai Food and Drug administration. Nation list of essential medicines [online]. 2016 [cited May 20, 2018]. Available from: drug.fda.mopg.gp.th:81/nlem. In.th/medicine/Essential/list/48
3. Siriangkhawut M, Uchalapichat V, Tansakul P. Mus culoskeletoal adverse event associated associated with simvastatin drug interactions and physician response to pharmacist interventions. Isan Journal of Pharmaceutical Sciences 2016; 11: 190-201
4. Siriangkhawut M, Tansakul P, Uchalapichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assess ment of musculoskeletal adverse events induced by statin interaction. Saudi Pharm J 2017; 25: 823-29
5. Jiang G, Liu H, Solbrig HR, Chute CG. Mining severe drug-drug interaction adverse events using Semantic Web technologies: a case study. Bio Data Min 2015; 8: 12. doi: 10.1186/s13040-015-00 44-6.
6. Office of Pharmacy Accreditation. Names and addresses of quality drugstores [online]. 2015 [cited Oct 3, 2017]. Available from: www.pharmacycouncil. org/index.php?option=content_detail&menuid=39&itemid=633&catid=0.
7. Michael B. Statin safety and drug interactions: Clinical Implications. AJC 2006; 97: 27-31
8. Tatro DS. Drug interaction facts. Missouri: Wolters Kluwer Health; 2011. p 860-86
9. Causevic-Ramosevac A, Semiz S. Drug interactions with statins. Acta Pharm. 2013; 63: 277–93.
10. Anantapong M, Futrakul W, Kongkiatkamon S. Development and implementation of drug-drug inter action prevention and management tools: Case studies in accredited community pharmacies in Bangkok [independent study]. Phitsanolok: Naresu an University; 2007.
11. Hylton LA, Flurie RW, Lajthia E, Dixon DL. Clinical guidance for managing statin and antimicrobial drug-drug interactions. Curr Atheroscler Rep. 2017; 19: 46. doi: 10.1007/s11883-017-0682-x.
12. Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB. et al. Recommendations for manage ment of clinically significant drug-drug Interactions with statins and select agents used in patients with cardiovascular disease. Circulation. 2016; 134: e468 -e495.
13. Indermitte J, Beutler M, Bruppacher R, Meier CR, Hersberger KE. Managemrnt of drug interaction alerts in community pharmacies. J Clin Pharm Ther 2007; 32: 133-42.
14. Arkaravichien W , Patcharapanukul P, Wattanapi taksakul N, Pheukpan J, Rattanasaeng P, Hannok S. Satisfaction to simple printed materials to support pharmaceutical care in community pharmacies. Srinagarind Medical Journal 2017; 32: 220-8.
